Antipsychotics TDM Market size was valued at USD 222,1 Million in 2021 and is poised to grow at a significant CAGR of 5.8% over 2022-2028. Antipsychotic pharmaceuticals are medications that are used to treat psychosis, such as schizophrenia and bipolar illness. Psychosis is a serious sign of mental disease that includes a loss of touch with reality, which affects how one processes information. On the bases of drug type, the risperidone segment is anticipated to hold the major market revenue share in the forecasting market owing to Risperidone is a medication that is used to treat a variety of mental and emotional problems (such as schizophrenia, bipolar disorder, irritability associated with autistic disorder). This drug can assist you in thinking clearly and participating in daily activities. Moreover, the in Feb 2019 Indivior PLC launched of once-monthly PERSERI (risperidone) for extended-release injectable suspension in the United States. PERSERIS is approved by the U.S. Food and Drug Administration for the treatment of schizophrenia in adults. PERSERIS delivers its active ingredient, risperidone, in an extended-release delivery system with no loading doses or oral supplementation recommended., Antipsychotic medicine demand is increasing as the prevalence of psychosis and associated disorders rises. Genetic abnormalities, substance-induced psychoses, and physical sickness leading to depression are some of the key causes contributing to the rising prevalence of these disorders.
Antipsychotics TDM Market Key Developments:
June 2020 Sumitomo Dainippon Pharmas atypical antipsychotic agent, LATUDA tablets were launched in Japan. The introduction of the drug is expected to strengthen the company’s position in the country.
Fastest Growing Market
A key growth driver for the market is the rising frequency of mental health diseases such as schizophrenia and bipolar disorder among the population. Anxiety disorders are the most frequent mental ailment in the United States, impacting 40 million persons aged 18 and over, or 18.1 percent of the population each year, according to the Anxiety and Depression Association of America. Anxiety disorders affect about half of the persons who have been diagnosed with depression.
The antipsychotics tdm market is projected to expand at a CAGR of 5.8% during the forecast period.
Roche Diagnostics, Sekisui Diagnostics, Thermo Fischer Scientific, Beckman Coulter, ChromSystems
Asaia Pacific is the fastest-growing region for antipsychotics tdm market